霍奇金淋巴瘤复发、难治的相关因素分析

 目的　探讨霍奇金淋巴瘤（HL）复发、难治的相关因素，分析复发、难治性HL患者的生存情况。方法　对62例HL患者的临床资料进行回顾性分析，对其临床特征、治疗方法等与复发、难治的关系进行相关性分析。结果　62例HL患者中，12例（19.35 %）为复发、难治性。病理类型（P＝0.026）、淋巴结区≥3个（P＝0.030）和大包块（P＝0.006）与复发、难治有关。复发、难治性HL患者中位生存时间为69.5个月（27～129个月），复发、难治性HL及其他HL患者的5年总生存（OS）率分别为66.7 %和88.8 %，二组差异无统计学意义（P＝0.117），无事件生存（EFS）率分别为52.4 %和87.9 %，差异有统计学意义（P＝0.006）。结论　HL的病理类型、淋巴结区≥3个和大包块与复发、难治关系密切，同时，短期（<1年）内复发是复发、难治性HL患者的不良预后因素，值得关注。

Related factors analysis of relapsed refractory Hodgkin lymphoma

Objective　To investigate the related factors of relapsed refractory Hodgkin lymphoma (HL), analysis treatment and adverse reactions. Methods　Clinical features and treatment outcome of 62 HL patients were analyzed retrospectively. Results　Of the 62 HL patients, 12 patients(19.35 %) were relapsed refractory HL. Pathologic type (P = 0.026), lymph node area ≥3 (P = 0.030) and large mass (P = 0.006) were important factors for relapsed and refractory. The median overall survival time of relapsed refractory HL was 69.5 months (27-129 months). The 5 year overall survival (OS) rates in relapsed refractory HL and others were 66.7 % and 88.8 % respectively (P = 0.117). The 5 year event-free survival (EFS) rates in relapsed refractory HL were 52.4 % and others 87.9 % respectively (P = 0.006). Conclusion　Pathologic type, lymph node area ≥3 and large mass are closely related with refractory refractory HL. At the same time, recurrence in the short-term (< 1 year) is the independent prognostic factor for patients with relapsed refractory HL.